Overview of seminal fluid biomarkers for the evaluation of chronic prostatitis: a scoping review

Moryousef, Joseph; Blankstein, Udi; Nickel, J. Curtis; Krakowsky, Yonah; Gilron, Ian; Jarvi, Keith

doi:10.1038/s41391-021-00472-8

Cited by 4 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo experiments verified that the Dex nanoformulations can significantly relieve CPPS in EAP mice, which inspired us to further investigate the anti-inflammatory mechanism of these NPs in EAP mice. Proinflammatory cytokines, including TNF-α and IL-1β, play a crucial role in the pathogenesis of CP, and their expression is closely related to the inflammatory response and prostate tissue destruction [ 34 ]. In addition, IL-17 plays an important part in the pathogenesis of EAP and may indirectly cause pelvic pain associated with CP [ 29 ].…”

Section: Resultsmentioning

confidence: 99%

Glucocorticoid nanoformulations relieve chronic pelvic pain syndrome and may alleviate depression in mice

Yang

Zheng

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Background Chronic pelvic pain syndrome (CPPS) is a typical symptom of chronic prostatitis (CP) in males that may cause abnormal urination, sexual dysfunction, or depression and significantly affect the quality of life of the patient. Currently, there is no effective treatment for CPPS due to its recurrence and intractability. For synergistic CPPS therapy, we developed pH/reactive oxygen species (ROS) dual-responsive dexamethasone (Dex) nanoformulations using a ROS-responsive moiety and phytochemical modified α-cyclodextrin (α-CD) as the carrier. Results Dex release from the nanoformulations can be controlled in acidic and/or ROS-rich microenvironments. The fabricated Dex nanoformulations can also be efficiently internalized by lipopolysaccharide (LPS)-stimulated macrophages, prostatic epithelial cells, and stromal cells. Moreover, the levels of proinflammatory factors (e.g., TNF-α, IL-1β, and IL-17 A) in these cells were significantly decreased by Dex nanoformulations treatment through the release of Dex, phytochemical and elimination of ROS. In vivo experiments demonstrated notable accumulation of the Dex nanoformulations in prostate tissue to alleviate the symptoms of CPPS through the downregulation of proinflammatory factors. Interestingly, depression in mice may be relieved due to alleviation of their pelvic pain. Conclusion We fabricated Dex nanoformulations for the effective management of CPPS and alleviation of depression in mice.

show abstract

Section: Resultsmentioning

confidence: 99%

Glucocorticoid nanoformulations relieve chronic pelvic pain syndrome and may alleviate depression in mice

Yang

Zheng

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Proin ammatory cytokines, including TNF-α and IL-1β, play a crucial role in the pathogenesis of CP, and their expression is closely related to the in ammatory response and prostate tissue destruction 34 . In addition, IL-17 plays an important part in the pathogenesis of EAP and may indirectly cause pelvic pain associated with CP 29 .…”

Section: Anti-in Ammatory Of the Dex Nanoformulations In Eap Micementioning

confidence: 99%

Glucocorticoid nanoformulations relieve chronic pelvic pain syndrome and may alleviate depression in mice

Yang

Zheng

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Chronic pelvic pain syndrome (CPPS) is a typical symptom of chronic prostatitis (CP) in males that may cause abnormal urination, sexual dysfunction, or depression and significantly affect the quality of life of the patient. Currently, there is no effective treatment for CPPS due to its recurrence and intractability. For synergistic CPPS therapy, we developed pH/reactive oxygen species (ROS) dual-responsive dexamethasone (Dex) nanoformulations using a ROS-responsive moiety and phytochemical modified α-cyclodextrin (α-CD) as the carrier. Results Dex release from the nanoformulations can be controlled in acidic and/or ROS-rich microenvironments. The fabricated Dex nanoformulations can also be efficiently internalized by lipopolysaccharide (LPS)-stimulated macrophages, prostatic epithelial cells, and stromal cells. Moreover, the levels of proinflammatory factors (e.g., TNF-α, IL-1β, and IL-17A) in these cells were significantly decreased by Dex nanoformulations treatment through the release of Dex, phytochemical and elimination of ROS. In vivo experiments demonstrated notable accumulation of the Dex nanoformulations in prostate tissue to alleviate the symptoms of CPPS through the downregulation of proinflammatory factors. Interestingly, depression in mice may be relieved due to alleviation of their pelvic pain. Conclusion We fabricated Dex nanoformulations for the effective management of CPPS and alleviation of depression in mice.

show abstract

Biomarkers in Alzheimer’s disease

Rajendran,

Krishnan

2024

Clinica Chimica Acta

View full text Add to dashboard Cite

Overview of seminal fluid biomarkers for the evaluation of chronic prostatitis: a scoping review

Cited by 4 publications

References 49 publications

Glucocorticoid nanoformulations relieve chronic pelvic pain syndrome and may alleviate depression in mice

Glucocorticoid nanoformulations relieve chronic pelvic pain syndrome and may alleviate depression in mice

Glucocorticoid nanoformulations relieve chronic pelvic pain syndrome and may alleviate depression in mice

Biomarkers in Alzheimer’s disease

Contact Info

Product

Resources

About